VBI Vaccines has entered into a research collaboration with GlaxoSmithKline Biologicals SA to evaluate VBI’s LPV Platform. VBI’s LPV Platform is a proprietary formulation and process that enables the development of vaccines and biologics with improved stability and preserved potency. GSK has the option to negotiate an exclusive license to VBI’s LPV Platform for use in a defined field. “With our partners, we seek to develop a next generation of vaccines and biologics with improved stability...